phrykt

Adma Biologics, Inc. (ADMA): who owns it and who trades it

As of Nov 16, 2026, ADMA insiders reported 14 open-market sales worth $3.8M and 5 purchases worth $468K in the last 12 months, with 55% of the sale value made under pre-set 10b5-1 plans. The largest seller was Adam S Grossman (CEO), with $3.5M. 8 of the 50 famous funds we follow held it at their last quarter end.

Latest filing Nov 16, 2026. From Form 4, 13F and Schedule 13D/G filings.

At a glance

Who is buying and selling ADMA Biologics

From the latest filings

Overall: more selling than buying. Funds and insiders mostly sold. Famous investors was close to even.

Mostly sellingEvenMostly buying

Each group counts equally in the meter, by the number of buyers and sellers, not dollars. Insider sales under pre-set 10b5-1 plans are left out of it. From SEC, House and Senate filings; not advice.

Who owns ADMA

321 funds and institutions reported ADMA shares worth $1.7B at the end of Q2 2026, about 90% of the company. The largest holder is BlackRock, Inc. with 16.5%.

Funds and institutions (13F) 90%Everyone else 10%

10 largest owners, by share of the company

BlackRock, Inc.16.5%
State Street Corp7.4%
Vanguard Capital Management LLC4.4%
Vanguard Portfolio Management LLC4.4%
Rubric Capital Management LP4.0%
Capital Research Global Investors3.8%
First Trust Advisors LP3.4%
Geode Capital Management, LLC2.6%
Caligan Partners LP2.5%
D. E. Shaw & Co., Inc.2.3%

Top 20 owners

OwnerShares% of companyValueChange since Q1 2026
BlackRock, Inc.38.36M16.55%$321M+4%
State Street Corp17.12M7.38%$143M+22%
Vanguard Capital Management LLC10.10M4.36%$84.6M-2%
Vanguard Portfolio Management LLC10.09M4.35%$84.4M+14%
Rubric Capital Management LP9.34M4.03%$78.2M+416%
Capital Research Global Investors8.76M3.78%$73.3M-22%
First Trust Advisors LP7.80M3.36%$65.3M+2065%
Geode Capital Management, LLC6.06M2.61%$50.7M+4%
Caligan Partners LP5.73M2.47%$47.9M+20%
D. E. Shaw & Co., Inc.5.27M2.28%$44.1M+841%
Nantahala Capital Management, LLC4.72M2.04%$39.5M–
Dimensional Fund Advisors LP3.61M1.56%$30.2M-28%
Goldman Sachs Group Inc3.51M1.52%$29.4M+25%
B Group, Inc.3.26M1.41%$27.3M+2%
Nuveen, LLC3.26M1.41%$27.3M-47%
Duquesne Family Office LLC2.78M1.20%$23.3M+80%
Northern Trust Corp2.42M1.04%$20.2M+6%
Morgan Stanley2.27M0.98%$19M-7%
Ranger Investment Management, L.P.2.12M0.91%$17.7M-7%
Charles Schwab Investment Management Inc2.09M0.90%$17.5M-0%

From the SEC 13F data sets: every fund manager with over $100M must report its US stock holdings every 3 months, up to 45 days after the quarter ends. Owners are shown as they file, so one group (for example Vanguard) can appear under several names. Individuals, most insiders and smaller funds do not file 13F reports.

Insider trades

In the last 12 months, ADMA insiders reported $468K of open-market purchases and $3.8M of sales. 55% of the sale value was under a 10b5-1 plan, a schedule set up in advance.

Purchases, 12 months
$468K
5 trades, 2 people
Sales, 12 months
$3.8M
14 trades, 3 people
Sales under a 10b5-1 plan
55%
Share of sale value
Latest trade
Nov 16, 2026
Filed Nov 16, 2026

Purchases and sales by month

$2.2M$2.2MDecFebAprJunAugOct
Purchases Sales Click a bar to show only that month below

Latest trades

DateInsiderRoleTypeSharesPriceValueFiling
Nov 16, 2026Adam S GrossmanCEOSale plan15,000$13.72$206KForm 4
Nov 16, 2026Adam S GrossmanCEOSale plan6,000$13.72$82.3KForm 4
Nov 16, 2026Lawrence P. GuiheenDirectorSale10,000$13.92$139KForm 4
Nov 5, 2026Adam S GrossmanCEOSale plan105,000$12.00$1.3MForm 4
Nov 5, 2026Adam S GrossmanCEOSale plan42,000$12.00$504KForm 4
May 27, 2026Jerrold B GrossmanDirectorPurchase6,400$7.91$50.6KForm 4
May 12, 2026Jerrold B GrossmanDirectorPurchase12,500$8.01$100KForm 4
May 11, 2026Jerrold B GrossmanDirectorPurchase12,500$8.01$100KForm 4
Mar 16, 2026Adam S GrossmanCEOSale6,000$15.16$91KForm 4
Mar 16, 2026Adam S GrossmanCEOSale15,000$15.16$227KForm 4
Mar 9, 2026Kaitlin M. Kestenberg-MessinaVice presidentSale10,096$15.63$158KForm 4
Mar 6, 2026Steve ElmsDirectorPurchase7,000$15.39$108KForm 4
Mar 5, 2026Steve ElmsDirectorPurchase7,000$15.67$110KForm 4
Feb 17, 2026Adam S GrossmanCEOSale6,000$16.08$96.5KForm 4
Feb 17, 2026Adam S GrossmanCEOSale15,000$16.08$241KForm 4
Dec 15, 2025Adam S GrossmanCEOSale6,000$19.79$119KForm 4
Dec 15, 2025Adam S GrossmanCEOSale15,000$19.79$297KForm 4
Nov 19, 2025Adam S GrossmanCEOSale6,000$16.00$96KForm 4
Nov 19, 2025Adam S GrossmanCEOSale15,000$16.00$240KForm 4

Insiders by value traded

InsiderRoleBoughtSoldLast trade
Adam S GrossmanPresident and CEO, Director–$3.5MNov 16, 2026
Jerrold B GrossmanDirector$251K–May 27, 2026
Steve ElmsDirector$217K–Mar 6, 2026
Kaitlin M. Kestenberg-MessinaCOO and SVP, Compliance–$158KMar 9, 2026
Lawrence P. GuiheenDirector–$139KNov 16, 2026
What this data shows, and what it doesn't
  • Shows: open-market purchases and sales by officers, directors and 10%+ owners, reported on Form 4 within two business days of the trade.
  • Leaves out: stock awards, option exercises, shares withheld for tax and gifts. These are not trades at a market price chosen by the insider.
  • "plan" marks a sale made under a Rule 10b5-1 plan, a schedule set up in advance.
  • Fund holders come from 13F reports, a snapshot at quarter end filed up to 45 days later.
  • Filings are self-reported and can be amended. Each trade links to its original filing. Methodology

ADMA short interest

Moderate short interest. 8.1% of ADMA shares are sold short: about 1 share in 12. Over the last 12 reports the number of shares short went down 10%.

As a rough guide, under 5% is low, 5–10% is moderate, 10–20% is high and over 20% is very high.

0%5%10%15%20%+

As of Oct 30, 2026, 18.04M ADMA shares were sold short, 8.1% of the shares outstanding, down 7.6% from the report before. At the average daily volume of 2.54M shares, buying them all back would take about 7.1 trading days (days to cover).

Shares short, % of all shares

8.13%May 15Oct 3011.2%

Days to cover

7.1May 15Oct 3015.6

Every report

Settlement dateShares short% of sharesChangeAvg daily volumeDays to cover
Oct 30, 202618.04M8.13%-8%2.54M7.1
Oct 15, 202619.53M8.72%-5%2.98M6.5
Sep 30, 202620.60M9.20%-15%3.63M5.7
Sep 15, 202624.21M10.81%+1%2.24M10.8
Aug 31, 202623.87M10.66%+5%1.72M13.9
Aug 14, 202622.68M10.13%+3%2.84M8.0
Jul 31, 202621.92M9.79%-9%2.48M8.8
Jul 15, 202624.03M10.37%-1%2.64M9.1
Jun 30, 202624.23M10.46%+14%4.17M5.8
Jun 15, 202621.28M9.18%+7%3.28M6.5
May 29, 202619.90M8.58%-0%3.30M6.0
May 15, 202619.99M8.63%-3%8.84M2.3

Short sellers borrow shares and sell them, hoping to buy them back for less. A high number means many such bets are open. It does not say where the price will go. Source: FINRA equity short interest, reported by brokers twice a month (positions on the 15th and the last business day) and published about 7 business days later. % of shares uses the share count on the company's latest SEC filing. What short interest means · Most shorted stocks

ADMA Biologics company events

ADMA Biologics filed 9 reports on Form 8-K in the last 12 months, 1 of them about an important change (leadership). The latest was on Nov 4, 2026.

  1. Nov 4, 2026ResultsReleased financial results. Filing
  2. Aug 5, 2026ResultsReleased financial results. Filing
  3. Jun 2, 2026VoteReported shareholder vote results. Filing
  4. May 6, 2026ResultsReleased financial results. Filing
  5. May 4, 2026AnnouncementADMA Biologics, Inc. issued a press release announcing that the U.S. Food and Drug Administration has approved the Company’s label expansion supplemental Biologics License Application for ASCENIV TM to include pediatric immune compromised patients two years of age and older. Filing
  6. Mar 27, 2026AnnouncementShared information with investors. Filing
  7. Mar 2, 2026AnnouncementOf this Current Report on Form 8-K. The press release is furnished hereto as Exhibit 99.1* and is incorporated by reference herein. Filing
  8. Feb 25, 2026LeadershipBrad Tade notified the Company that he is retiring from his position as Chief Financial Officer and Treasurer of the Company effective at the close of business on February 25, 2026, following the filing of the Company’s Annual Report on Form 10-K for the year ended December 31, 2025. Filing
  9. Jan 12, 2026ResultsReleased financial results. Filing

From 8-K reports, which a company must file within 4 business days of an important event. Where a report is about a change such as a new CEO, the sentence is the first one from the report itself, shortened. Each row links to the original filing. Company events this week

ADMA Biologics financials

Famous investors that hold ADMA

8 of the 50 well-known investors we track reported holding ADMA in their latest 13F filing. The largest position is Stanley Druckenmiller's, worth $22.2M.

Position size

All holders

FundQuarterSharesValueOf portfolioChange
Stanley Druckenmiller · Duquesne Family OfficeQ3 20262.21M$22.2M0.5%-21%
Israel Englander · Millennium ManagementQ3 20261.72M$17.2M0.0%+49%
Terry Smith · FundsmithQ3 20261.65M$16.5M0.1%No change
Ray Dalio · Bridgewater AssociatesQ3 2026975,642$9.8M0.0%+143%
Jim Simons · Renaissance TechnologiesQ3 2026532,468$5.3M0.0%-18%
Ken Griffin · Citadel AdvisorsQ3 2026469,687$4.7M0.0%-66%
Paul Tudor Jones · Tudor Investment CorpQ3 2026147,376$1.5M0.0%New
Steve Cohen · Point72 Asset ManagementQ3 202698,197$985K0.0%-76%

From 13F reports: a snapshot at quarter end, filed up to 45 days later. Change compares with the quarter before.

5%+ stakes filed in the last 120 days

Anyone who owns more than 5% of a company must report it on Schedule 13D or 13G. 4 filings named ADMA in the last 120 days.

FiledHolderFormStake
Nov 16, 2026Rubric Capital Management LP13G5.5%
Nov 16, 2026Rubric Capital Management LP13G5.5%
Nov 10, 2026STATE STREET CORPORATION13G6.1%
Nov 10, 2026STATE STREET CORPORATION13G6.1%

Questions about Adma Biologics, Inc. (ADMA) stock

Who owns the most ADMA stock?

The largest reported owner of Adma Biologics, Inc. (ADMA) is BlackRock, Inc., with 16.5% of the company. In total, 321 funds and institutions reported holding ADMA at the end of Q2 2026, together about 90% of the shares. See the largest owners.

Are ADMA insiders buying or selling?

In the last 12 months, ADMA insiders reported 5 open-market purchases worth $468K and 14 sales worth $3.8M. The latest trade was on Nov 16, 2026. See every trade.

What is the short interest in ADMA?

As of Oct 30, 2026, 18.04M ADMA shares were sold short, 8.1% of the shares outstanding, down 7.6% from the report before. At the average daily volume of 2.54M shares, buying them all back would take about 7.1 trading days (days to cover). See the history.

Which famous investors hold ADMA?

8 of the 50 well-known investors we track reported ADMA in their latest 13F filing, including Stanley Druckenmiller, Israel Englander, Terry Smith. The largest position is worth $22.2M. See all holders.

Executive pay

ADMA Biologics's chief executive was paid a total of $10.2M for the year ended Dec 31, 2025, up 29% from $7.9M the year before. In the last 12 months, ADMA Biologics's executives and directors bought $468K of stock on the open market and sold $3.8M.

Chief executive, total pay$10.2MYear ended Dec 31, 2025. Salary, bonus and the value of stock and option awards when granted.
Pay "actually paid"$13.6MThe same year, with stock awards valued at what they were worth as they vested or at year end.
Other top executives, average$2.9MThe other officers named in the proxy statement.

From the pay versus performance table in the company's annual proxy statement (DEF 14A), as the company reported it. If the chief executive changed during the year, the company reports each person separately and this shows one of them.

Source: SEC Form 4 (insiders, filed within 2 business days), 13F (funds, up to 45 days after quarter end) and Schedule 13D/13G filings. Only open-market purchases (code P) and sales (code S) are shown. Data only, not investment advice. How we collect it.